Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy
Restricted accessLetterFirst published online 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy
HoySM.Deucravacitinib: first approval. Drugs. 2022;82(17):1671-1679. doi:10.1007/s40265-022-01796-y
2.
ArmstrongAWGooderhamMWarrenRB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39. doi:10.1016/j.jaad.2022.07.002
3.
StroberBThaçiDSofenH, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40-51. doi:10.1016/j.jaad.2022.08.061
4.
HaginoTSaekiHFujimotoEKandaN.Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatolog Treat. 2024;35(1):2307489. doi:10.1080/09546634.2024.2307489
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
